tooluniverse-chemical-safety

name

tooluniverse-chemical-safety

description

Comprehensive chemical safety and toxicology assessment integrating ADMET-AI predictions, CTD toxicogenomics, FDA label safety data, DrugBank safety profiles, and STITCH chemical-protein interactions. Performs predictive toxicology (AMES, DILI, LD50, carcinogenicity), organ/system toxicity profiling, chemical-gene-disease relationship mapping, regulatory safety extraction, and environmental hazard assessment. Use when asked about chemical toxicity, drug safety profiling, ADMET properties, environmental health risks, chemical hazard assessment, or toxicogenomic analysis.

Chemical Safety & Toxicology Assessment

Comprehensive chemical safety analysis integrating predictive AI models, curated toxicogenomics databases, regulatory safety data, and chemical-biological interaction networks.

When to Use This Skill

Triggers:

• "Is this chemical toxic?" / "Assess the safety profile of [drug/chemical]"
• "What are the ADMET properties of [SMILES]?"
• "What genes does [chemical] interact with?" / "What diseases are linked to [chemical] exposure?"
• "Drug safety assessment" / "Environmental health risk" / "Chemical hazard profiling"

Use Cases:

1. Predictive Toxicology: AI-predicted endpoints (AMES, DILI, LD50, carcinogenicity, hERG) via SMILES
2. ADMET Profiling: Absorption, distribution, metabolism, excretion, toxicity
3. Toxicogenomics: Chemical-gene-disease mapping from CTD
4. Regulatory Safety: FDA label warnings, contraindications, adverse reactions
5. Drug Safety: DrugBank safety + FDA labels combined
6. Chemical-Protein Interactions: STITCH-based interaction networks
7. Environmental Toxicology: Chemical-disease associations for contaminants

---

KEY PRINCIPLES

1. Report-first approach - Create report file FIRST, then populate progressively
2. Tool parameter verification - Verify params via get_tool_info before calling unfamiliar tools
3. Evidence grading - Grade all safety claims by evidence strength (T1-T4)
4. Citation requirements - Every toxicity finding must have inline source attribution
5. Mandatory completeness - All sections must exist with data or explicit "No data" notes
6. Disambiguation first - Resolve compound identity (name -> SMILES, CID, ChEMBL ID) before analysis
7. Negative results documented - "No toxicity signals found" is data; empty sections are failures
8. Conservative risk assessment - When evidence is ambiguous, flag as "requires further investigation"
9. English-first queries - Always use English chemical/drug names in tool calls

---

Evidence Grading System (MANDATORY)

Tier	Symbol	Criteria	Examples
T1	[T1]	Direct human evidence, regulatory finding	FDA boxed warning, clinical trial toxicity
T2	[T2]	Animal studies, validated in vitro	Nonclinical toxicology, AMES positive, animal LD50
T3	[T3]	Computational prediction, association data	ADMET-AI prediction, CTD association
T4	[T4]	Database annotation, text-mined	Literature mention, unvalidated database entry

Evidence grades MUST appear in: Executive Summary, Toxicity Predictions, Regulatory Safety, Chemical-Gene Interactions, Risk Assessment.

---

Core Strategy: 8 Research Phases

Chemical/Drug Query
|
+-- PHASE 0: Compound Disambiguation (ALWAYS FIRST)
|   Resolve name -> SMILES, PubChem CID, ChEMBL ID, formula, weight
|
+-- PHASE 1: Predictive Toxicology (ADMET-AI)
|   AMES, DILI, ClinTox, carcinogenicity, LD50, hERG, skin reaction
|   Stress response pathways, nuclear receptor activity
|
+-- PHASE 2: ADMET Properties
|   BBB penetrance, bioavailability, clearance, CYP interactions, physicochemical
|
+-- PHASE 3: Toxicogenomics (CTD)
|   Chemical-gene interactions, chemical-disease associations
|
+-- PHASE 4: Regulatory Safety (FDA Labels)
|   Boxed warnings, contraindications, adverse reactions, nonclinical tox
|
+-- PHASE 5: Drug Safety Profile (DrugBank)
|   Toxicity data, contraindications, drug interactions
|
+-- PHASE 6: Chemical-Protein Interactions (STITCH)
|   Direct binding, off-target effects, interaction confidence
|
+-- PHASE 7: Structural Alerts (ChEMBL)
|   PAINS, Brenk, Glaxo structural alerts
|
+-- SYNTHESIS: Integrated Risk Assessment
    Risk classification, evidence summary, data gaps, recommendations

See phase-procedures-detailed.md for complete tool parameters, decision logic, output templates, and fallback strategies for each phase.

---

Tool Summary by Phase

Phase 0: Compound Disambiguation

• PubChem_get_CID_by_compound_name (name: str)
• PubChem_get_compound_properties_by_CID (cid: int)
• ChEMBL_get_molecule (if ChEMBL ID available)

Phase 1: Predictive Toxicology

• ADMETAI_predict_toxicity (smiles: list[str]) - AMES, DILI, ClinTox, LD50, hERG, etc.
• ADMETAI_predict_stress_response (smiles: list[str])
• ADMETAI_predict_nuclear_receptor_activity (smiles: list[str])

Phase 2: ADMET Properties

• ADMETAI_predict_BBB_penetrance / _bioavailability / _clearance_distribution / _CYP_interactions / _physicochemical_properties / _solubility_lipophilicity_hydration (all take smiles: list[str])

Phase 3: Toxicogenomics

• CTD_get_chemical_gene_interactions (input_terms: str)
• CTD_get_chemical_diseases (input_terms: str)

Phase 4: Regulatory Safety

• FDA_get_boxed_warning_info_by_drug_name / _contraindications_ / _adverse_reactions_ / _warnings_ / _nonclinical_toxicology_ / _carcinogenic_mutagenic_fertility_ (all take drug_name: str)

Phase 5: Drug Safety

• drugbank_get_safety_by_drug_name_or_drugbank_id (query, case_sensitive, exact_match, limit - all 4 required)

Phase 6: Chemical-Protein Interactions

• STITCH_resolve_identifier (identifier: str, species: 9606)
• STITCH_get_chemical_protein_interactions (identifiers: list[str], species: int, required_score: int)

Phase 7: Structural Alerts

• ChEMBL_search_compound_structural_alerts (molecule_chembl_id: str)

---

Risk Classification Matrix

Risk Level	Criteria
CRITICAL	FDA boxed warning OR multiple [T1] toxicity findings OR active DILI + active hERG
HIGH	FDA warnings OR [T2] animal toxicity OR multiple active ADMET endpoints
MEDIUM	Some [T3] predictions positive OR CTD disease associations OR structural alerts
LOW	All ADMET endpoints negative AND no FDA/DrugBank flags AND no CTD concerns
INSUFFICIENT DATA	Fewer than 3 phases returned data

---

Report Structure

# Chemical Safety & Toxicology Report: [Compound Name]
**Generated**: YYYY-MM-DD | **SMILES**: [...] | **CID**: [...]

## Executive Summary (risk classification + key findings, all graded)
## 1. Compound Identity (disambiguation table)
## 2. Predictive Toxicology (ADMET-AI endpoints)
## 3. ADMET Profile (absorption, distribution, metabolism, excretion)
## 4. Toxicogenomics (CTD chemical-gene-disease)
## 5. Regulatory Safety (FDA label data)
## 6. Drug Safety Profile (DrugBank)
## 7. Chemical-Protein Interactions (STITCH network)
## 8. Structural Alerts (ChEMBL)
## 9. Integrated Risk Assessment (classification, evidence summary, gaps, recommendations)
## Appendix: Methods and Data Sources

See report-templates.md for full section templates with example tables.

---

Mandatory Completeness Checklist

• Phase 0: Compound disambiguated (SMILES + CID minimum)
• Phase 1: At least 5 toxicity endpoints or "prediction unavailable"
• Phase 2: ADMET A/D/M/E sections or "not available"
• Phase 3: CTD queried; results or "no data in CTD"
• Phase 4: FDA labels queried; results or "not FDA-approved"
• Phase 5: DrugBank queried; results or "not found"
• Phase 6: STITCH queried; results or "no data available"
• Phase 7: Structural alerts checked or "ChEMBL ID not available"
• Synthesis: Risk classification with evidence summary
• Evidence Grading: All findings have [T1]-[T4] annotations
• Data Gaps: Explicitly listed

---

Common Use Patterns

1. Novel Compound: SMILES -> Phase 0 (resolve) -> Phase 1 (toxicity) -> Phase 2 (ADMET) -> Phase 7 (structural alerts) -> Synthesis
2. Approved Drug Review: Drug name -> All phases (0-7) -> Complete safety dossier
3. Environmental Chemical: Chemical name -> Phase 0 -> Phase 1-2 -> Phase 3 (CTD, key) -> Phase 6 (STITCH) -> Synthesis
4. Batch Screening: Multiple SMILES -> Phase 0 -> Phase 1-2 (batch) -> Comparative table -> Synthesis
5. Toxicogenomic Deep-Dive: Chemical + gene/disease interest -> Phase 0 -> Phase 3 (expanded CTD) -> Literature -> Synthesis

---

Limitations

• ADMET-AI: Computational [T3]; should not replace experimental testing
• CTD: May lag behind latest literature by 6-12 months
• FDA: Only covers FDA-approved drugs; not applicable to environmental chemicals
• DrugBank: Primarily drugs; limited industrial chemical coverage
• STITCH: Lower score thresholds increase false positives
• ChEMBL: Structural alerts require ChEMBL ID; not all compounds have one
• Novel compounds: May only have ADMET-AI predictions (no database evidence)
• SMILES validity: Invalid SMILES cause ADMET-AI failures

---

Reference Files

• phase-procedures-detailed.md - Complete tool parameters, decision logic, output templates, fallback strategies per phase
• evidence-grading.md - Evidence grading details and examples
• report-templates.md - Full report section templates with example tables
• phase-details.md - Additional phase context
• test_skill.py - Test suite

---

Summary

Total tools integrated: 25+ tools across 6 databases (ADMET-AI, CTD, FDA, DrugBank, STITCH, ChEMBL)

Best for: Drug safety assessment, chemical hazard profiling, environmental toxicology, ADMET characterization, toxicogenomic analysis

Outputs: Structured markdown report with risk classification (Critical/High/Medium/Low), evidence grading [T1-T4], and actionable recommendations